Search clinical trials for: sintilimab metronomic PLOF

Total 524 results

Huashan Hospital

Recruiting

Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer

Gastric Cancer

China
Assiut University

Completed

Sagittal Parameters After Mono Segmental Lumber Fusion: Interbody Versus Postrolateral Fusion

Lumbar Spine Fusion

Egypt
Exactech

Terminated

Evaluation of Radiographic and Patient Outcomes Following Lumbar Spine Fusion Using Demineralized Bone Matrix (DBM) Mixed With Autograft

Degenerative Disc Disease | Spondylolisthesis | Stenosis

United States
Immune Design

Terminated

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Melanoma | Sarcoma | Ovarian Cancer | Non-small Cell Lung Cancer

United States
Unity Health Toronto

Withdrawn

Review and Assessment of Network Meta-analyses for Knowledge Uptake Study (RANK)

Clinical Decision-making
Nicklaus Children's Hospital f/k/a Miami Children...
Florida International University

Completed

Use of a Metronome in Cardiopulmonary Resuscitation: A Simulation Study

Cardiac Arrest
University of Oxford

Completed

CommunICation of bEnefit Risk Information: an Online Randomised Controlled Trial (CICERO)

Knowledge, Attitudes, Practice | Literacy | Confidence, Self

United Kingdom
NuVasive

Completed

A Prospective Non-concurrent Controlled Evaluation of Open and MAS® PLIF

Lumbar Degenerative Disc Disease

United States
Beijing Tiantan Hospital

Recruiting

Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma

Meningioma, Malignant

China
Ruijin Hospital

Unknown

Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
RemeGen Co., Ltd.

Recruiting

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Advanced Solid Tumours

China
Peking University People's Hospital

Unknown

Correlation Between the Lower Extremities and Lumbar Degenerative Diseases of the Elderly

Lumbar Osteoarthritis
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

Advanced or Metastatic NSCLC

China
University of Minnesota

Completed

An Evaluation of the Efficacy of Oral-B New Product Sensi-Stop on Dentinal Hypersensitivity (SSDH)

Tooth Sensitivity

United States
Cliniques universitaires Saint-Luc- Université...

Completed

Autocorrelated Rhythmic Auditory Stimulations for Parkinson's Disease Patients

Parkinson Disease
The Defense and Veterans Brain Injury Center

Completed

"Interactive Metronome Technology for Blast-Related Traumatic Brain Injury"

Traumatic Brain Injury | Post-Concussion Syndrome

United States
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
Hasselt University
Jessa Hospital; Sint-Trudo Hospital; Sint-Franciscus Ziekenhuis

Suspended

Extreme Lateral Interbody FusionFUSION (XLIF) Versus Posterior Lumbar Interbody Fusion (PLIF) (XLIF)

Atrophy | Muscle Damage | Degenerative Diseases, Spinal Cord

Belgium
Wuhan University

Recruiting

The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors

Pediatric Cancer

China
Zhejiang Cancer Hospital

Not yet recruiting

Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma

Esophageal Cancer | Elderly Patients | Immunotherapy | Sintilimab | Chemoradiotherapy
Zhejiang Cancer Hospital

Recruiting

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

Esophageal Squamous Cell Carcinoma

China
Peking Union Medical College Hospital

Recruiting

SinTilimab After Radiation (STAR Study) (STAR)

Carcinoma, Non-Small Cell Lung

China
The First Hospital of Jilin University

Active, not recruiting

Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer (STARS-RC03)

Locally Advanced Rectal Cancer | PD-1 | Total Neoadjuvant Treatment | Tislelizumab

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients (ORIENT-4)

Effect of Drugs

China
Centre Hospitalier Universitaire de Nice

Recruiting

sFlt-1/PlGF Ratio: Impact on the Management of Patients With Suspected Pre-eclampsia (PROSPE)

Pre-Eclampsia

France
Shanghai YingLi Pharmaceutical Co. Ltd.

Recruiting

A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Children's Medical Center

Not yet recruiting

Study on Sintilimab in Stage IV High Risk Neuroblastoma (SCMC-S-2020)

Recurrent Stage IV High Risk Neuroblastoma

China
West China Hospital

Not yet recruiting

Sintilimab in FH-deficient Renal Cell Carcinoma

Renal Cell Carcinoma | Sintilimab | FH-deficient
M.D. Anderson Cancer Center
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab in Cancer of Unknown Primary

Cancer of Unknown Primary Site

United States
Henan Cancer Hospital

Active, not recruiting

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
University of North Carolina, Chapel Hill

Completed

The Effects of Auditory Cues on Gait Mechanics in Parkinson's Disease

Parkinson Disease

United States
Karl Landsteiner Institute for Lung Research and...

Completed

Can Austrian Lung Specialists' Assessments of Lung Cancer Screening be Influenced by a Fact Box?"

Lung Cancer

Austria
Assistance Publique - Hôpitaux de Paris
INSERM CESP1018

Completed

Preeclampsia Ratio (sFlt-1/PlGF) (PRECOG)

Preeclampsia

France
Ningbo No.2 Hospital

Not yet recruiting

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY)

Carcinoma, Non-Small-Cell Lung
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Donafenib Plus Sintilimab for Advanced HCC

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

China
Henan Cancer Hospital

Completed

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Extensive Disease Small Cell Lung Cancer

China
Shanghai Cancer Hospital, China

Unknown

Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study

Lung Neoplasms

China
Chinese PLA General Hospital

Unknown

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

Metastasis Colorectal Cancer

China
Shandong Cancer Hospital and Institute

Unknown

Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC (CONSIST)

Carcinoma, Non-Small Cell Lung

China
Wuhan Union Hospital, China

Not yet recruiting

Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Stomach Neoplasms

China
The Fourth Affiliated Hospital of Zhejiang University...
Second Affiliated Hospital, School of Medicine, Zhejiang University

Recruiting

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...
First People's Hospital of Hangzhou; First Affiliated Hospital of Zhejiang... and other collaborators

Recruiting

Orelabrutinib and Sintilimab in Relapsed or Refractory Central Nervous System Lymphoma

Primary Central Nervous System Hodgkin Lymphoma

China
Henan Provincial People's Hospital

Not yet recruiting

Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Peking University Third Hospital; Dongzhimen Hospital, Beijing; Beijing Longfu...

Recruiting

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Cutaneous T-cell Lymphoma

China
RenJi Hospital

Active, not recruiting

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

Stomach Neoplasms

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

Advanced Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

NSCLC (Non-small-cell Lung Cancer)

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization (STOP)

Precancerous Conditions | Oral Cavity Cancer | Mouth Neoplasm

China

Search clinical trials for: sintilimab metronomic PLOF

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations